FDA restricts Johnson & Johnson COVID-19 vaccine due to risks of blood clots
- FDA: Investigation into Multistate Salmonella Outbreak Linked to Jif Peanut Butter
- ABBV-951: AbbVie submits new drug application for Parkinson’s disease
- Alert: Monkeypox belongs to the same genus of Orthopoxvirus as smallpox
- New study finds new coronavirus long-term hiding in intestine and feces
- New breakthrough: This collagen can make tumor cells go dormant!
- Lilly’s blockbuster new hair loss drug is expected to be launched this year
FDA restricts Johnson & Johnson COVID-19 vaccine due to risks of blood clots
- Unexplained acute hepatitis in children may be related to COVID superantigens
- How long can the patient live after heart stent surgery?
- Keytruda: The 5-year survival rate for advanced lung cancer doubled!
- Amylyx released the latest statistical analysis of new ALS drugs after being opposed by FDA panel last month
- Celine Dion is paralyzed due to muscle cramps: What are Muscle Cramps?
- Taiwan death from COVID-19 vaccination exceeds death from COVID-19
- The world top 5 best-selling drugs in 2020
FDA restricts Johnson & Johnson COVID-19 vaccine due to risks of blood clots
On May 05, U.S. Food and Drug Administration (FDA) announced on the same day that they would limit the emergency use authorization of Johnson & Johnson’s COVID-19 vaccine because it May cause rare and dangerous thrombocytopenic blood clots in recipients.
With immediate effect, Johnson & Johnson’s COVID-19 vaccine in the United States will be limited to adults over the age of 18 who cannot receive other vaccines.
Screenshot from CNN website
Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said the center has been monitoring the incidence of thrombocytopenic blood clots following Johnson & Johnson’s COVID-19 vaccine and is updating the emergency use authorization through its “safety surveillance system.” .
Marks said that the FDA’s move this time reflects the power of the “safety surveillance system” and also shows that they are determined to use science and data to guide action.
CNN confirmed to the FDA that this restriction also applies to booster shots.
The FDA believes that for certain groups of people, the risks of J&J’s COVID-19 vaccine already outweigh the benefits, but they can still receive J&J’s COVID-19 vaccine for the following groups: Severe allergic reaction to Pfizer or Moderna’s mRNA COVID-19 vaccine Those who have personal doubts about the mRNA COVID-19 vaccine, if they do not receive the Johnson & Johnson COVID-19 vaccine, they will not be vaccinated; those who cannot receive the mRNA COVID-19 vaccine.
According to the U.S. Centers for Disease Control and Prevention (CDC), more than 18.7 million doses of Johnson & Johnson’s COVID-19 vaccine have been administered in the United States. Among those in the U.S. who have been fully vaccinated, 7.7% of the people who received the Johnson & Johnson vaccine were vaccinated.
According to the FDA’s statistics as of March 18, they have confirmed 60 cases of thrombocytopenic blood clots after vaccination with Johnson & Johnson’s COVID-19 vaccine, including 9 deaths.
Should Johnson & Johnson COVID-19 vaccine be used for booster?
FDA restricts Johnson & Johnson COVID-19 vaccine due to risks of blood clots
(source:internet, reference only)
Disclaimer of medicaltrend.org
